Real Chemistry announced a pair of senior hires on Thursday, highlighted by the appointment of IPG and Omnicom alum Jeff ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

Under the terms of the deal, Bedford, Mass.-based Stoke (STOK) will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen ...

Several large Massachusetts employers have filed annual reports with federal securities regulators that are notable for ...

Boston Properties (NYSE:BXP) reported its fourth-quarter earnings for 2024, revealing a significant shortfall in earnings per share (EPS) compared to market forecasts. The company posted an EPS of -$1 ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...